Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Chief Legal & Admin Officer | March 15, 2026 | March 17, 2026 |
| EXELIXIS, INC.EXEL · Entity 3386 | EVP & General Counsel | May 15, 2025 | May 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date March 15, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,943 |
Reported balance
After 2026-03-15 transaction · row 1
1 source rowRow 1 · 2026-03-15 · Grant · Acquired 20,646 · Balance 107,943 F1: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.06 · Expires 2036-03-14 | Direct | 8,325 |
Reported balance
After 2026-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-15 · Grant · Acquired 8,325 · Balance 8,325 F2: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.06 · Expires 2036-03-14 | Direct | 22,820 |
Reported balance
After 2026-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-15 · Grant · Acquired 22,820 · Balance 22,820 F3: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
F2: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
F3: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
EXELIXIS, INC.
Report date May 15, 2025 · Filed May 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 693,396 |
Last balance in matching sequence
After 2025-05-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-05-15 · Tax withholding · Disposed 34,035 · Balance 718,396 F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2021, March 4, 2022, April 3, 2023, and February 23, 2024. F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Row 2 · 2025-05-15 · Sale · Disposed 25,000 · Balance 693,396 F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.04 to $46.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 999 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 999 F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2021, March 4, 2022, April 3, 2023, and February 23, 2024.
F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock.
F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.04 to $46.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2017 Filed Mar 29, 2017 00:15 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 6,884 | $21.02 | $144,701.68 |
DisclosureSEC source: 0000939767-17-000048 · wf-form4_149074648798636.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,946 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.03. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-17-000045 · wf-form4_149039885489826.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 55,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 23,787 | $20.54 | $488,584.98 |
DisclosureSEC source: 0000939767-17-000045 · wf-form4_149039885489826.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,830 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.53 to $20.58. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 55,000 | $1.70 | $93,500.00 |
DisclosureSEC source: 0000939767-17-000045 · wf-form4_149039885489826.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 16, 2017 Filed Mar 24, 2017 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000045 · wf-form4_149039885489826.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,830 Read SEC document |
| March 03, 2017 Filed Mar 8, 2017 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0000939767-17-000031 · wf-form4_148893478684185.xml · derivative · entry 5 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 100,000 shares Expires 2021-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 230,000 shares of Exelixis, Inc. common stock, was exercisable as to 172,500 shares on the Transaction Date. The remainder of the option will vest as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the February 10, 2014 grant date. Read SEC document |
| March 03, 2017 Filed Mar 8, 2017 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 59,482 | $23.05 | $1,371,060.10 |
DisclosureSEC source: 0000939767-17-000031 · wf-form4_148893478684185.xml · nonDerivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,617 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.03 to $23.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 03, 2017 Filed Mar 8, 2017 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 3,519 | $23.20 | $81,640.80 |
DisclosureSEC source: 0000939767-17-000031 · wf-form4_148893478684185.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,099 Read SEC document |
| March 03, 2017 Filed Mar 8, 2017 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 36,999 | $23.00 | $850,977.00 |
DisclosureSEC source: 0000939767-17-000031 · wf-form4_148893478684185.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,618 Read SEC document |
| March 03, 2017 Filed Mar 8, 2017 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 100,000 | $7.27 | $727,000.00 |
DisclosureSEC source: 0000939767-17-000031 · wf-form4_148893478684185.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 23:43 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 97,500 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-16-000258 · wf-form4_147493338611685.xml · derivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2024-09-21 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2014 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 23:43 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-16-000258 · wf-form4_147493338611685.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,617 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2014 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on November 15, 2017, and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each November 15th until fully-vested. F3 · balance_after: Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.